Pfizer has submitted new data to the US Food and Drug Administration (FDA) demonstrating the stability of the vaccine when stored at -25C to -15C, temperatures more commonly found in pharmaceutical freezers. The data submitted to the FDA is to support a proposed update to the Emergency Use Authorization (EUA) Prescribing Information.

If approved, the update would allow for vaccine vials to be stored at these temperatures for a total of two weeks, as an alternative or complement to storage in ultra-low temperature freezers.